MA44379A - Fusions variant iii du récepteur du facteur de croissance épidermique-mésothéline et leurs procédés d'utilisation - Google Patents

Fusions variant iii du récepteur du facteur de croissance épidermique-mésothéline et leurs procédés d'utilisation

Info

Publication number
MA44379A
MA44379A MA044379A MA44379A MA44379A MA 44379 A MA44379 A MA 44379A MA 044379 A MA044379 A MA 044379A MA 44379 A MA44379 A MA 44379A MA 44379 A MA44379 A MA 44379A
Authority
MA
Morocco
Prior art keywords
mesothelin
epidermal
methods
growth factor
factor receptor
Prior art date
Application number
MA044379A
Other languages
English (en)
Inventor
William G Hanson
Peter M Lauer
Original Assignee
Aduro Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aduro Biotech Inc filed Critical Aduro Biotech Inc
Publication of MA44379A publication Critical patent/MA44379A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/001168—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA044379A 2015-04-13 2016-04-12 Fusions variant iii du récepteur du facteur de croissance épidermique-mésothéline et leurs procédés d'utilisation MA44379A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562146559P 2015-04-13 2015-04-13
US201562243397P 2015-10-19 2015-10-19

Publications (1)

Publication Number Publication Date
MA44379A true MA44379A (fr) 2019-01-23

Family

ID=55809232

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044379A MA44379A (fr) 2015-04-13 2016-04-12 Fusions variant iii du récepteur du facteur de croissance épidermique-mésothéline et leurs procédés d'utilisation

Country Status (22)

Country Link
US (1) US10105427B2 (fr)
EP (1) EP3283509A1 (fr)
JP (1) JP6782253B2 (fr)
KR (1) KR20180002640A (fr)
CN (1) CN107750256A (fr)
AU (1) AU2016247887A1 (fr)
BR (1) BR112017022076A2 (fr)
CA (1) CA2982533A1 (fr)
CO (1) CO2017011431A2 (fr)
CR (1) CR20170507A (fr)
EA (1) EA201792274A1 (fr)
EC (1) ECSP17075380A (fr)
HK (2) HK1250992A1 (fr)
IL (1) IL254957A0 (fr)
MA (1) MA44379A (fr)
MX (1) MX2017013174A (fr)
PH (1) PH12017502080A1 (fr)
SG (1) SG11201708360TA (fr)
SV (1) SV2017005545A (fr)
TW (1) TW201710285A (fr)
UY (1) UY36616A (fr)
WO (1) WO2016168198A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107750256A (zh) 2015-04-13 2018-03-02 艾杜罗生物科技公司 表皮生长因子受体变体iii‑间皮素融合物及其使用方法
JP2018512165A (ja) 2015-04-13 2018-05-17 アデュロ バイオテック，インコーポレイテッド 癌の治療のための免疫原性融合タンパク質
US20170199961A1 (en) 2015-12-16 2017-07-13 Gritstone Oncology, Inc. Neoantigen Identification, Manufacture, and Use
ES3029080T3 (en) 2017-10-10 2025-06-23 Seattle Project Corp Neoantigen identification using hotspots
US11885815B2 (en) 2017-11-22 2024-01-30 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830702A (en) 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
US7635479B2 (en) 2000-03-29 2009-12-22 The Trustees Of The University Of Pennsylvania Composition and methods for enhancing immunogenecity of antigens
US6051237A (en) 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
DE69532767T2 (de) 1994-11-28 2004-08-12 Thomas Jefferson University Peptid umfassend eine Sequenz aus einer Fusionsverbindungsstelle in einem mutierten EGF-Rezeptor vom Typ III
WO2004006837A2 (fr) 2002-07-12 2004-01-22 The Johns Hopkins University Vaccins a la mesotheline et systemes de modele
JP2006514823A (ja) 2002-08-20 2006-05-18 ミレニアム ファーマスーティカルズ インク 子宮頸癌の同定、評価、予防および治療を行うための組成物、キットおよび方法
JP4545151B2 (ja) 2003-02-06 2010-09-15 シーラス コーポレイション 非食細胞中への侵入について減弱化されているリステリア、そのリステリアを含むワクチン、およびそれらの使用法
WO2004084936A2 (fr) 2003-02-06 2004-10-07 Cerus Corporation Microbes modifies vivant en milieu naturel, compositions de vaccins, et procedes d'utilisation correspondants
JP5283335B2 (ja) 2003-06-17 2013-09-04 マンカインド コーポレイション 各種癌の治療を目的とした腫瘍関連抗原の組合せ
US7935804B2 (en) 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
JP5347135B2 (ja) * 2006-03-01 2013-11-20 アドゥロ バイオテック 遺伝子工学操作されたｌｉｓｔｅｒｉａおよびその使用方法
WO2007117371A2 (fr) 2006-03-01 2007-10-18 Anza Therapeutics, Inc. Listeria de fabrication humaine et ses procédés d'utilisation
SI2640842T1 (sl) 2010-11-17 2018-09-28 Aduro Biotech, Inc. Postopki in sestavki za induciranje imunskega odziva na EGFRvIII
SG11201502792TA (en) * 2012-12-27 2015-05-28 Aduro Biotech Inc Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof
CN104211814A (zh) * 2013-05-29 2014-12-17 三星电子株式会社 用于消耗靶膜蛋白的组合物
JP2018512165A (ja) 2015-04-13 2018-05-17 アデュロ バイオテック，インコーポレイテッド 癌の治療のための免疫原性融合タンパク質
CN107750256A (zh) 2015-04-13 2018-03-02 艾杜罗生物科技公司 表皮生长因子受体变体iii‑间皮素融合物及其使用方法

Also Published As

Publication number Publication date
JP2018512166A (ja) 2018-05-17
HK1250992A1 (zh) 2019-01-18
ECSP17075380A (es) 2018-02-28
EP3283509A1 (fr) 2018-02-21
CO2017011431A2 (es) 2018-01-16
HK1250730A1 (zh) 2019-01-11
BR112017022076A2 (pt) 2018-08-14
AU2016247887A1 (en) 2017-11-02
US10105427B2 (en) 2018-10-23
EA201792274A1 (ru) 2018-02-28
UY36616A (es) 2016-10-31
IL254957A0 (en) 2017-12-31
TW201710285A (zh) 2017-03-16
CA2982533A1 (fr) 2016-10-20
JP6782253B2 (ja) 2020-11-11
WO2016168198A1 (fr) 2016-10-20
SG11201708360TA (en) 2017-11-29
KR20180002640A (ko) 2018-01-08
PH12017502080A1 (en) 2018-05-07
MX2017013174A (es) 2018-04-11
US20160346369A1 (en) 2016-12-01
CN107750256A (zh) 2018-03-02
CR20170507A (es) 2018-02-13
SV2017005545A (es) 2018-05-11

Similar Documents

Publication Publication Date Title
IL304117A (en) Anti-pvrig antibodies and methods of use
EP3436030A4 (fr) Récepteurs chimériques et leurs procédés d'utilisation
IL262095A (en) Anti-pacap antibodies and uses thereof
IL259747A (en) Antibodies targeting fc receptor-like 5 and methods of use
KR20180084817A (ko) 항-siglec-9 항체 및 이의 이용 방법
IL254734B1 (en) Modified t cells and methods of making and using the same
PL3353210T3 (pl) Przeciwciała anty-TIGIT i sposoby stosowania
PL3250610T3 (pl) Przeciwciała anty-FcRn i sposoby ich stosowania
EP3350508A4 (fr) Lucarne artificielle et procédés
EP3368571A4 (fr) Polypeptides sensibles au facteur de croissance transformant bêta et leurs procédés d'utilisation
IL271260A (en) Multi-specific antibodies and methods of making and using thereof
MA47849A (fr) Anticorps anti-gitr et leurs procédés d'utilisation
EP3310305A4 (fr) Greffe aortique ramifiée et son procédé d'utilisation
CL2016001868A1 (es) Proteinas de union y sus métodos de uso
EP3368538A4 (fr) Inhibiteurs de la kinase wee 1 et leurs procédés de fabrication et d'utilisation
SI3303394T1 (sl) Protitelesa proti-CTLA-4 in postopki njihove uporabe
PL3215532T3 (pl) Przeciwciała anty-TIM3 i sposoby ich zastosowania
PL3280441T3 (pl) Przeciwciała przeciwko sortilinie i sposoby ich stosowania
MA40921A (fr) Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation
EP3394065A4 (fr) Tétrahydropyranyl-amino-pyrrolopyrimidinone et procédés d'utilisation associés
IL271257A (en) Multi-specific antibodies and methods of making and using thereof
EP3303435A4 (fr) Hydrofluoroléfines et procédés d'utilisation associés
DK3200791T3 (da) Fremgangsmåder og mellemprodukter i fremstilling af C5AR- antagonister
IL254670A0 (en) Humanized anti-c1s antibodies and methods of use thereof
EP3319610A4 (fr) Oxystérols et leurs procédés d'utilisation